Results 111 to 120 of about 7,229 (203)

Satisfaction and Treatment Burden Among Early Adopters of Long-Acting Injectable Cabotegravir-Rilpivirine With and Without Viremia in Three US Ryan White Clinics. [PDF]

Open Forum Infect Dis
Christopoulos KA, Beckert A, McCracken C, Dance K, Plotkin S, Collins LF, McNulty MC, Hickey MD, Johnson MO, Mody A, Erguera XA, Koester KA, Liegeon G, Salazar J, Gutierrez J, Grochowski J, Dilworth SE, Neilands TB, Montgomery ET, Colasanti JA.   +19 more
europepmc   +1 more source

Ultrasound for the determination of appropriate needle length for intragluteal injection of long-acting rilpivirine-cabotegravir. [PDF]

HIV Med
Gueuning C, Brizmohun M, Dauby N, Martin C.   +3 more
europepmc   +1 more source

Brief Report: Real-World Uptake and Clinical Outcomes of Long-Acting Injectable Cabotegravir/Rilpivirine in the United States, 2021-2023. [PDF]

J Acquir Immune Defic Syndr
O'Shea J, Derton A, Henson J, Iqbal K, Briggs-Hagen M, Kourtis AP, Buchacz K.   +6 more
europepmc   +1 more source

Impact of implementation process on long-acting cabotegravir/rilpivirine prescription at 9 HIV clinics, 2021-2024. [PDF]

J Acquir Immune Defic Syndr
Lujintanon S, Lesko CR, Haw NJL, Hickey MD, Zalla LC, Kilcrease C, Grochowski J, Hill LA, Cachay ER, Budak JZ, Crane HM, Fleming J, Mayer KH, Rutstein SE, Turner B, Nevin C, Burkholder GA, Wang N, Yendewa GA, Moss R, Pettit A, Rodriguez AE, Johnson MO, Christopoulos KA.   +23 more
europepmc   +1 more source

Changes in RPV Resistance-Related Mutations Among Antiretroviral Therapy-Naïve HIV-1-Positive Individuals - China, 2004-2023. [PDF]

China CDC Wkly
Li X, Liu X, Xin P, Wang D, Hao J, Song C, Hu J, Feng Y, Ruan Y, Xing H, Liao L.   +10 more
europepmc   +1 more source

Effectiveness of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People with HIV on Any Antiretroviral Therapy Regimen: The Retrospective ESSENTIAL Study. [PDF]

Infect Dis Ther
Cossu MV, Moschese D, Matone M, Oreni L, Carrozzo G, Poloni A, Pozza G, Albini L, Forcina G, Gervasoni C, Riva A, Giacomelli A, Gori A.   +12 more
europepmc   +1 more source

Beyond Surveillance Mutations: Long-Term Trends and Clinical Relevance of Transmitted HIV Drug Resistance in Spain (2007-2023). [PDF]

Open Forum Infect Dis
Muñoz Báez P, Illescas López M, de Salazar A, Falces Romero I, Pinto A, Portilla I, Masiá M, Peraire J, Alemán Valls MR, Sanchiz M, Iborra A, Baza B, Aguilera A, Olalla J, Espinosa N, Iribarren JA, Gisbert L, Imaz A, Montero M, Navarro Marcotegui M, Suárez-García I, Riera M, Pérez Elias MJ, Galán JC, García Fraile LJ, Sanz J, Ibarra Ugarte S, Bernal E, Blanco JR, Navarro G, Martínez O, Viciana Ramos MI, Mohamen-Balghata MO, Delgado E, Thompson MM, Moreno C, CoRIS C, Fuentes A, García F.   +38 more
europepmc   +1 more source

Choosing between dual and three-drug antiretroviral therapy in aging and comorbid people with HIV: a narrative review. [PDF]

Front Reprod Health
Cossu MV, Matone M, Iannone V, Fusetti C, Colombo V, Gori A, Ridolfo AL, Gervasoni C.   +7 more
europepmc   +1 more source

Real-World Safety and Effectiveness of Cabotegravir in People Living with HIV: Interim Report of a Post-marketing Surveillance in Japan. [PDF]

Adv Ther
Yoshikawa Y, Nagao T, Matsukawa T, Maeno Y, Sebata A, Suzuki M, Ibe S, Fukuda A, Wang D.   +8 more
europepmc   +1 more source

Need for Medication Review and Deprescribing in People Living with HIV: A Longitudinal Observational Study. [PDF]

Pharmaceuticals (Basel)
De Bellis E, Donnarumma D, Pagano A, Mazza I, Charlier B, Madonia S, Masullo A, Onofrio M, Fortunato V, Spera AM, Campana F, Franci G, Salzano F, Corbi G, Filippelli A, Pagliano P, Conti V.   +16 more
europepmc   +1 more source